Published in Antimicrob Agents Chemother on June 23, 2008
Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo. Biochem Pharmacol (2014) 0.80
Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis. PLoS One (2016) 0.75
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol (2007) 2.27
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA (2005) 1.80
Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses (2002) 1.66
The glycylcyclines: a comparative review with the tetracyclines. Drugs (2004) 1.64
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS (2002) 1.58
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS (2003) 1.41
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology (2006) 1.16
Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.13
High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.07
Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol (1997) 1.06
Evaluation of the hepatotoxic potential of minocycline. Antimicrob Agents Chemother (1991) 0.98
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2004) 0.97
Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder. Ann Pharmacother (2005) 0.93
Concentration-targeted therapy and the future of HIV management. AIDS (2002) 0.88
Interaction of cimetidine with tetracycline absorption. Lancet (1980) 0.79
Possible theophylline-minocycline interaction. Ann Pharmacother (1992) 0.78
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J Infect Dis (2013) 2.29
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr (2007) 2.17
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol (2010) 1.95
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Long-QT syndrome after age 40. Circulation (2008) 1.73
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS (2002) 1.68
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer (2011) 1.62
Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol (2011) 1.59
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med (2008) 1.53
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol (2006) 1.48
Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage (2004) 1.40
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr (2006) 1.40
Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci (2007) 1.39
A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging (2003) 1.34
Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis (2004) 1.34
Quantification of accuracy and precision of multi-center DTI measurements: a diffusion phantom and human brain study. Neuroimage (2011) 1.30
Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol (2010) 1.22
Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol (2007) 1.22
A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging (2005) 1.17
Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol (2011) 1.15
Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis (2012) 1.08
Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost (2011) 1.07
Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis (2007) 1.07
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2009) 1.07
Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol (2007) 1.06
Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy. Muscle Nerve (2004) 1.02
Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2009) 1.02
Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol (2006) 1.02
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment. Neuroimage Clin (2013) 1.01
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother (2009) 1.01
Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis (2009) 1.00
Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol (2006) 1.00
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol (2009) 1.00
Evaluation of measurement uncertainties in human diffusion tensor imaging (DTI)-derived parameters and optimization of clinical DTI protocols with a wild bootstrap analysis. J Magn Reson Imaging (2009) 1.00
Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol (2011) 0.99
Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol (2009) 0.98
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis (2009) 0.98
Team performance and risk-adjusted health outcomes in the Program of All-Inclusive Care for the Elderly (PACE). Gerontologist (2006) 0.98
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2004) 0.97
The relation between posttraumatic stress disorder and mild traumatic brain injury acquired during Operations Enduring Freedom and Iraqi Freedom. J Head Trauma Rehabil (2013) 0.95
Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol (2013) 0.95
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials (2007) 0.94
Program characteristics and enrollees' outcomes in the Program of All-Inclusive Care for the Elderly (PACE). Milbank Q (2007) 0.94
T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition. Heart Rhythm (2011) 0.93
Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis (2013) 0.93
Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study. J Neurovirol (2012) 0.92
Ethics of sham surgery: perspective of patients. Mov Disord (2008) 0.92
Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials (2010) 0.91
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J Pharm Biomed Anal (2007) 0.91
The life and death of oligodendrocytes in vanishing white matter disease. J Neuropathol Exp Neurol (2004) 0.90
Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol (2010) 0.90
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr (2004) 0.89
Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol (2011) 0.88
Noninvasive vascular elastography using plane-wave and sparse-array imaging. IEEE Trans Ultrason Ferroelectr Freq Control (2013) 0.88
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 0.87
Social support and risk-adjusted mortality in a frail older population. Med Care (2004) 0.87
Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals. J Neurovirol (2011) 0.87
Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture. J Neurovirol (2004) 0.86
NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther (2013) 0.86
SPatial REgression Analysis of Diffusion tensor imaging (SPREAD) for longitudinal progression of neurodegenerative disease in individual subjects. Magn Reson Imaging (2013) 0.85
Chronic stress in nonelderly caregivers: psychological, endocrine and immune implications. J Psychosom Res (2002) 0.85
Simplification of the research diagnosis of HIV-associated sensory neuropathy. HIV Clin Trials (2009) 0.84
Variations in risk-adjusted outcomes in a managed acute/long-term care program for frail elderly individuals. Int J Qual Health Care (2004) 0.83
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Antivir Ther (2010) 0.83
Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy (2010) 0.82
Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure. Circ Heart Fail (2013) 0.82
Can serum procalcitonin levels help interpret indeterminate chest radiographs in patients hospitalized with acute respiratory illness? J Hosp Med (2012) 0.82
Changes in ventricular repolarization duration during typical daily emotion in patients with Long QT syndrome. Psychosom Med (2010) 0.82
Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals. PLoS One (2013) 0.81
Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
In-hospital mortality among women undergoing contemporary elective percutaneous coronary intervention: a reexamination of the gender gap. Clin Cardiol (2006) 0.81
Happiness and stress alter susceptibility to cardiac events in Long QT Syndrome. Ann Noninvasive Electrocardiol (2009) 0.81
Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm (2008) 0.80
Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.79
Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol (2014) 0.79
Factors associated with symptomatic rhinovirus infection in patients with COPD. J Clin Virol (2012) 0.79
Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients. J Neurovirol (2013) 0.78
Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults. Ann Pharmacother (2009) 0.78
Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm (2011) 0.78